Use of Maillard reaction inhibitors for the treatment of amyloid

Details Use of Maillard reaction inhibitors for the treatment of amyloid Use of Maillard reaction inhibitors for the treatment of amyloid

1998-12-04

2000-03-07

Weddington, Kevin E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514 31, 514311, 514634, A61K 31535, A61K 3170, A61K 3147, A61K 31155

Patent

active

060340800

ABSTRACT:
Inhibitors of the Maillard reaction are useful in the treatment or prophylaxis of amyloidosis-based disease, particularly Alzheimer's disease. Particular examples include aminoguanidine and amphotericin B.

REFERENCES:
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5202333 (1993-04-01), Berger et al.
patent: 5403861 (1995-04-01), Goldin et al.
patent: 5422360 (1995-06-01), Miyajima et al.
patent: 5453514 (1995-09-01), Niigata et al.
patent: 5891873 (1999-04-01), Colaco et al.
Pocchiari, M. et al., "Amphotericin B: A Novel Class of Antiscrapie Drugs," J Infect Dis (1989) 160(5):795-802.
Brown, P., "A Therapeutic Panorama of the Spongiform Encephalopathies," Antiviral Chem Chemother (1990) 1(2):75-84.
You et al., "Amphotericin B Treatment Dissociates in Vivo Replication of the Scrapie Agent from PrP Acumulation" Nature (1992)356:598-601.
Agrimi, U. et al., Medical Hypotheses 40:113-116 (1993).

Affiliated with

Also associated with

Rating

Use of Maillard reaction inhibitors for the treatment of amyloid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of Maillard reaction inhibitors for the treatment of amyloid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Maillard reaction inhibitors for the treatment of amyloid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-363291